Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol inhalation - Rapid Therapeutic Science Laboratories

Next Previous
X
Search
Drug Profile

Cannabidiol inhalation - Rapid Therapeutic Science Laboratories

Alternative Names: Cannabidiol MDI - Rapid Therapeutic Science Laboratories; CBD Metered Dose Inhaler - Rapid Therapeutic Science Laboratories

Latest Information Update: 04 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rapid Therapeutic Science
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Antioxidants; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Anxiety disorders; Attention-deficit hyperactivity disorder; Depressive disorders; Insomnia; Pain

Most Recent Events

  • 28 Jul 2022 Rapid Therapeutic Science Laboratories announces intention to submit IND to US FDA for Depressive disorder, Anxiety disorder, Insomnia, Attention-deficit hyperactivity disorder and Pain in Q3 of 2022
  • 22 Jul 2022 Rapid Therapeutic Science plans a phase I trial for Depressive disorder, Anxiety disorder, Insomnia, Attention-deficit hyperactivity disorder and Pain in USA
  • 02 Jun 2021 Rapid Therapeutic Science Laboratories plans phase I trials in Depressive disorder, Anxiety disorder, Insomnia, Attention-deficit hyperactivity disorder and Pain in USA (Inhalation)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top